Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFESAVER: Convalescent Plasma in Elderly COVID-19 Patients
NCT04374526Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: Rate of COVID-19 progression at 14 days. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04374526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374526.